Welcome to NB Globe
A humble offering
A news source for parents about the advances in neuroblastoma research is envisioned here. My goal is to highlight interesting published research, bring attention to clinical trial openings, and report on presentations from oncology meetings. Like all “reporters” I do have a bias though, described in the About page.
There is so much I don’t know that I admit even suggesting such a source of information is very intimidating. But I would like to try. I am hoping astute readers will keep me accurate and on top of things.
Check back here for reports on the Chicago ASCO 2010 meeting June 4 – 8 (see interesting abstracts below) and the ANR 2010 meeting June 21 – 24 in Stockholm, Sweden. I was granted an ASCO Patient Advocate scholarship to travel to Chicago for the ASCO meeting in part due to volunteer efforts working on the Parent Handbook for CNCF, and my generous mother is paying for the trip to Stockholm to attend the ANR meeting.
I heartily welcome your corrections, criticisms, and comments.
High-risk neuroblastoma is a difficult disease and controversies continue, important questions remain unanswered, and too many children still die in spite of so many dedicated researchers who have spent their careers working toward improving survival rates. Even though I have lost my own son to neuroblastoma, I am encouraged to see the survival rate significantly improve in my own lifetime—in the 18+ years since my son was diagnosed. So I am a believer in research, and have seen with my own eyes that progress—though excruciatingly slow—is being accomplished.
If you are interested in being notified of posts here on neuroblastoma news, consider subscribing to the RSS feed to be notified of all the updates.
A sampling of some interesting abstracts from ASCO 2010:
- 9532 Phase I trial of lestaurtinib for children with refractory neuroblastoma (NB): A New Approach to Neuroblastoma Therapy (NANT) Consortium Study. Jane E. Minturn
- 9562 Reduced intensity conditioning regimen and allogeneic stem cell transplantation from related or unrelated HLA identical donor in high risk neuroblastoma. Arcangelo Prete
- 9563 Tandem stem cell transplantation as consolidation therapy for high risk neuroblastoma: The Childrens Healthcare of Atlanta experience. Muna Qayed
- 9529 A pediatric phase I trial and pharmacokinetic study of MLN8237, an oral selective small molecule inhibitor of aurora a kinase: A Children’s Oncology Group Phase I Consortium study. Yael P. Mosse
- 9516 MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study. Gregory A Yanik
- 9517 Racial and ethnic disparities in disease presentation and survival among children with neuroblastoma (NBL): A Children’s Oncology Group (COG) study. Susan Lerner Cohn, MD
- 9518 Clinical and biological features predictive of survival after relapse of neuroblastoma: A study from the International Neuroblastoma (NB) Risk Group (INRG) Database. Wendy B. London, PhD
- Discussion: Prognostic Variables in Neuroblastoma Andrew Pearson, MD, FRCP
If you go to ASCO abstracts you can search or browse the list of abstracts. If you have questions for the presenters, please post your questions in “comments” below.
More coming soon,
Donna Ludwinski
This work is licensed under a Creative Commons Attribution 3.0 Unported License.
